CAT gives opinion on experimental data for first SME
This article was originally published in Clinica
Executive Summary
The European Medicines Agency’s Committee for Advanced Therapies (CAT) has adopted its first opinion on the certification of experimental data generated for an advanced therapies medicinal product (ATMP) under development by a small or medium-sized enterprise (SME).